SUMMARY An analysis of 211 patients who had porcine xenograft valve replacements at Henry Ford Hospital between October 1971 and March 1974, was accomplished, with 100% follow-up. The follow-up period extended from 60-89 months after implantation. One hundred sixty-seven patients with 192 valves survived the perioperative period and were subjected to life table analysis. Hemodynamically significant porcine xenograft degeneration that required reoperation occurred in 18 patients, two of whom had infective endocarditis. Only four valves failed within 48 months of surgery. Ten of 42 (23.8%) patients with isolated aortic valve replacement and eight of 102 patients (7.8%) patients with isolated mitral valve replacement required reoperation (p < 0.01). In patients under 25 years of age, six of nine surviving patients had repeat operations. Our data indicate that porcine xenograft degeneration is related to the duration of implantation and the age of the patient at the time implantation was performed. In addition, porcine xenograft valves in the aortic position are more likely to degenerate than are those in the mitral position.
THE GLUTERALDEHYDE-prepared porcine xenograft is one of the most encouraging valve substitutes available. The initial highly satisfactory results reported with this prosthesis have resulted in its use for replacement of diseased aortic, mitral and tricuspid valves.' Although the porcine xenograft valve has good hemodynamic features and a low thromboembolic rate," 3' 4it has the same potential for late degeneration as other bioprosthetic valves.6 Recent reports have suggested a low incidence of degeneration in adult patients7 and a higher rate in children. 8 We recently described the echocardiographic characteristics of degenerated porcine xenografts.9 Because of these observations we analyzed the first 211 patients in whom a gluteraldehyde porcine xenograft was implanted at this institution. This enabled us to obtain a minimum 5-year follow-up in order to assess the long-term durability of the valve.
Methods
Two hundred eleven patients received 252 porcine valve xenografts between October 1971 and March 1974. All deaths during the initial hospitalization and up to I month postoperatively were considered perioperative deaths, and accounted for 44 patients. There were 167 surviving patients with 192 valves 1 month after surgery. Information on all these was obtained regarding cardiac status, hospital admissions after valve replacement, evidence of thromboembolic episodes and current medication. A further 42 patients died during the follow-up period, leaving 125 patients alive at the end of the study (March 1979) . Of these, 112 patients were evaluated at Henry Ford Hospital during a closing period (January through March 1979). The remaining 13 patients were unable to return for follow-up examination, but 12 were contacted by telephone and one by letter. If any symptoms were reported the patient's physician was contacted.
Xenograft valve failure was diagnosed if there was disruption or distortion of the valve mechanism resulting in a hemodynamic lesion necessitating xenograft replacement. All patients included under this definition of xenograft dysfunction thus had the valves replaced.
In this paper we assess the long-term durability of the porcine xenograft. Hence, the I-month mortality or perioperative mortality is not included in long-term survival statistics. Several reports3' and our current experience indicate that there is no difference in perioperative mortality when using xenografts compared with other valve prostheses. Patients who developed infective endocarditis and died during the course of therapy and in whom the cause of death was not due primarily to valve failure are not included in the definition of valve dysfunction. Also, patients who died without a necropsy being performed are not included as valve failures. Both of these groups are included in the overall mortality. Systemic thromboembolism was diagnosed if a persistent neurologic deficit occurred postoperatively or if absent or diminished peripheral pulses were noted. Bland systemic emboli to other viscera were not noted in this series.
Patients with large left atria and those with atrial fibrillation were anticoagulated and were maintained indefinitely on warfarin unless bleeding complications occurred.
Statistical analysis comparing the rate of reoperation in the mitral and aortic groups was done using the chi-square method for cumulative actuarial analysis, based on a generalized Kruskal-Wallis test.'0 Statistical analysis comparing valve degeneration between the younger patients (younger than 25 years) and older patients (older than 25 years) was done using standard chi-square testing.
Results
There were 192 porcine xenograft valve insertions in the 167 patients who survived longer than 1 month. One hundred two patients had mitral valve replacements, 42 aortic, 13 mitral and aortic, eight mitral and tricuspid and two mitral, aortic and tricuspid. Thus, 125 mitral, 57 aortic and 10 tricuspid porcine xenograft valves were followed long-term. The age range of the patients was 8-77 years (mean age 50 years). Nine patients were under 25 years. One hundred seventeen patients were female. At the end of the follow-up period, 84 patients with mitral, 27 with aortic, eight with aortic and mitral, one with mitral, aortic and tricuspid and five with mitral and tricuspid porcine xenografts (total 125 patients) were alive.
Actuarial survival curves for the group as a whole and for subsets of valve replacements are shown in figures 1-3. Figure 1 shows overall mortality for the 167 patients alive 1 month after surgery. A progressive and almost linear mortality is seen, with an 89-month cumulative survival of 72%. The timing of patients requiring reoperation as a result of valve failure is shown in figure 2 . The cumulative valve failure rate at 48 months was only 4%; however, in the next 30 months this figure almost tripled, with an additional 11% valve failures.
During the period of follow-up, 18 of the 167 had reoperation for replacement of the porcine xenograft valve ( fig. 2, table 1 ). In 15, this was necessary because of spontaneous dysfunction of the xenograft. There was no evidence of infective endocarditis either before surgery or on histologic examination of the removed valve. Two patients had had preoperative evidence of infective endocarditis (one aortic and one mitral) and one patient had a thickened aortic porcine valve replaced at a second operation to repair paravalvar leaks. The aortic valve was replaced in 10 of the 18 patients and the mitral valve in the remaining eight. Ten of the 42 patients (23.8%) with isolated aortic and eight of the 102 patients (7.8%) with isolated mitral porcine xenografts required reoperation. Using the life- figure 4 , and a tear in a mitral porcine xenograft at a commissure with involvement of two leaflets (patient 14) (table 1) in figure 5 .
Culture-proved infective endocarditis occurred in five patients, two of whom presented as valve failures. The latter two patients required valve replacement Early is less than 1 month after replacement; late is more than 1 month after replacement. 6 years and 5 years after a cerebrovascular accident that left them partially disabled.
All 112 patients examined from January 1979 to March 1979 had improved symptomatically compared with to their preoperative New York Heart Association classification.
Discussion
There is little doubt that prosthetic heart valve replacement has resulted in symptomatic improvement of survivors"-" and an increased overall survival of patients with valvular heart disease.'3'`However, the diversity and number of available valve prostheses bears witness to our failure to achieve a satisfactory valve substitute.'5 In 1969, Carpentier and his associates started using gluteraldehyde-prepared porcine xenografts, with encouraging results.'6 Since the Hancock porcine xenograft became readily available in 1971, it has been used extensively and most of the reports reveal a low incidence of valve failure.'-5 [17] [18] [19] In our series, 167 patients with 192 valves survived the perioperative period. Forty-two patients died during the subsequent follow-up period. Six of these died secondary to known valve failure. In 12 other patients, valvular degeneration occurred and required valve replacement. In our series only four of the 18 documented valve failures occurred within 48 months of insertion and one of these was associated with infective endocarditis. The incidence of valve degeneration increased significantly 4 years after operation ( fig. 2) . Failure occurred in 7.8% of the mitral xenograft valves and in 23.8% of the aortic valve replacements. This rate of valve failure may represent an optimistic view, because a proportion of the patients who died postoperatively with evidence of congestive heart failure and in whom a necropsy was not performed may have had undiagnosed valve degeneration. The incidence of valve dysfunction in other reported series is difficult to ascertain because of relatively abbreviated periods of follow-up. In a recent series reported by Cohn et al.,7 323 patients were reported, with a mean follow-up of 33 months. Only 58 patients in the series were followed for longer than 48 months and 29 were followed for more than 60 months, the latter comparable to our series. Nevertheless, seven patients developed valve dysfunction. Although the authors did not discuss the duration of implantation of the dysfunctioning valves, the incidence of dysfunction after 48 months is likely to be considerably higher than the reported incidence of 1.4% for the total group (seven of 323). Particularly noteworthy in our series is the finding that six of nine patients younger than age 25 years who survived the perioperative period had the xenograft replaced for valve-related problems. This high incidence of valve failure in younger patients has also been noted by Kutsche et A low incidence of thromboembolism was initially reported in patients with porcine xenograft valve replacements.3' 30-32 The 9.5% incidence of thromboembolic events occurring in our patients is, however, not surprising, considering that 48% of the patients had atrial fibrillation associated with left atrial enlargement preoperatively. Early thromboembolism occurs possibly secondary to preexisting atrial thrombi. In patients with atrial fibrillation and large left atria secondary to mitral valve dysfunction, continued stasis after valve replacement is likely, and may be aggravated by left ventricular dysfunction, an occasional occurrence in the group.33' 4' We recommend long-term anticoagulation after xenograft valve replacement in patients with atrial fibrillation, large left atria and residual left ventricular dysfunction.
In summary, after insertion, porcine xenograft valve failures increase in frequency 48 months after replacenment. The incidence of valve failures is high in young persons. The failure rate for the aortic xenograft is significantly higher than for the mitral xenograft. Thromboembolism still occurs, but appears to be primarily related to persistent atrial fibrillation. We recommend long-term anticoagulation in all patients with atrial fibrillation or large left atria. Despite these limitations of the gluteraldehydepreserved porcine xenograft, it is probably the best available valve prosthesis, particularly for the mitral position.
